Shop

Author at Microdose

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Health & Wellness

23 May 2023

Nonprofit Helps Patients Access Ketamine Therapy Treatments

MY Self Wellness Ketamine Clinic’s Nonprofit Organization, Warriors of Consciousness Helps Those Who Cannot Afford Psychedelic Ketamine Therapy Treatments...

By Microdose NewsDesk

Don’t Miss

22 May 2023

News You Might Have Missed: May 22nd 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed....

By Microdose NewsDesk

Industry

19 May 2023

Terran Biosciences Discovers New Psilocybin Salts and Polymorphs; Publishes Patent Application

Terran Biosciences discovers what may be the first new salts, co-crystals, and polymorphs of psilocybin in history, publishes PCT patent application, and files psilocybin Drug Master File (DMF) with FDA...

By Microdose NewsDesk

Law & Politics

19 May 2023

U.S. Government Announces $1.5 Million Grant For Psychedelics Research

Support for psychedelic research continues to gain acceptance at the federal level as the National Institute on Drug Abuse (NIDA) announces a funding grant for research into psychedelic medicine....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

18 May 2023

MindMed Announces Milestone in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

MindMed announced that the company’s Phase 2b study evaluating MM-120 (lysergide D-tartrate) for GAD is over 50% enrolled and dosed....

By Microdose NewsDesk

Don’t Miss

15 May 2023

News You Might Have Missed: May 15th, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed....

By Microdose NewsDesk

Finance

12 May 2023

COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights

COMPASS Pathways reported its financial results for the first quarter 2023 and gave an update on recent progress across its business....

By Microdose NewsDesk

Finance

12 May 2023

GH Research Reports First Quarter 2023 Financial Results and Business Highlights

GH Research has reported financial results for the first quarter ended March 31, 2023 and provided business highlights....

By Microdose NewsDesk

Finance

11 May 2023

Terran Biosciences announces publication of four patent applications of novel empathogens

Terran Biosciences announces publication of four PCT patent applications covering breakthroughs in novel empathogens, including improved versions of methylone, ethylone, MDEA, MDAI, and MBDB...

By Microdose NewsDesk

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.